Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™…
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.…
EU approves first oral GLP-1 RA to cut cardiovascular risk Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular…
AGC Biologics Seattle Facility Celebrates Milestone Year with Regulatory Approvals, Quality Achievements, and Leadership Expansion AGC Biologics, a leading global contract development and manufacturing organization (CDMO), has announced that its Seattle, Washington facility has achieved a series of remarkable milestones…
France Grants Reimbursed Compassionate Access for Agenus’ Botensilimab plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer In a significant development for patients with advanced colorectal cancer, Agenus Inc. (Nasdaq: AGEN), a biotechnology company at the forefront of immuno-oncology innovation, announced…
CyPath® Lung Demonstrates Diagnostic Power in Detecting Cancer Within Ground-Glass Nodules: A Case Study Highlighting bioAffinity Technologies’ Advancements in Noninvasive Lung Cancer Detection Lung cancer remains one of the deadliest forms of cancer worldwide, accounting for more deaths each year…
Corner Therapeutics Research Opens Door to Universal Flu Vaccine and Expands Promise for Cancer Immunotherapy Corner Therapeutics, a biotechnology company specializing in in vivo T cell modulation and immunotherapy, has announced groundbreaking findings that could reshape the future of vaccination…
Nature Medicine Publishes Phase 3 Data on Pridopidine, Offering Hope in Early-Stage Huntington’s Disease Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, together with its partner Ferrer, announced a significant milestone in the scientific and medical understanding…
Texas Expands Medical Cannabis Access with House Bill 46: A New Era for Patient For thousands of Texans who live each day with the burden of chronic pain, traumatic brain injuries, Crohn’s disease, cancer, and other serious conditions, September 1,…
Hope Biosciences Receives FDA RMAT Designation for Stem Cell Therapy in Relapsing-Remitting Multiple Sclerosis Hope Biosciences, a leading U.S.-based stem cell banking and cellular therapeutics manufacturer, has announced a major regulatory milestone that could reshape the future of treatment for…
Devonian Health Group Provides Strategic Corporate Update and Clarifies Details of Private Placement Financing Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory and fibrotic diseases,…
Ifinatamab Deruxtecan Receives Breakthrough Therapy Designation from FDA for Pretreated Extensive-Stage Small Cell Lung Cancer The oncology research landscape took a significant step forward this week with the announcement that ifinatamab deruxtecan (I-DXd), an investigational antibody-drug conjugate (ADC), has been…
